44.14% to Target, Seaport Global Reaffirms Buy Rating for Pacira Pharmaceuticals (PCRX) Stock; Inovio Pharmaceuticals, Inc. (INO) Had 8 Analysts Last Week

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Logo

Seaport Global currently has a $48.0000 target on the $1.36 billion market cap company or 44.14% upside potential. In an analyst note issued on Sunday morning, Pacira Pharmaceuticals (NASDAQ:PCRX) stock had its Buy Rating kept by analysts at Seaport Global.

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals had 41 analyst reports since August 10, 2015 according to SRatingsIntel. Aegis Capital maintained the stock with “Buy” rating in Thursday, June 1 report. H.C. Wainwright maintained it with “Buy” rating and $1300 target in Thursday, July 27 report. Maxim Group maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Thursday, June 1 with “Buy” rating. The rating was maintained by Maxim Group on Wednesday, September 9 with “Buy”. The firm has “Hold” rating given on Tuesday, August 9 by Maxim Group. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, October 5 report. Maxim Group maintained the shares of INO in report on Thursday, June 8 with “Buy” rating. The company was maintained on Thursday, May 25 by H.C. Wainwright. The stock has “Hold” rating by Zacks on Friday, August 14. The firm has “Overweight” rating given on Thursday, June 8 by PiperJaffray. See Inovio Pharmaceuticals, Inc. (NASDAQ:INO) latest ratings:

21/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
15/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $14.0 Maintain
15/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
13/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
23/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
12/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
03/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
28/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
25/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain

The stock decreased 3.75% or $0.18 during the last trading session, reaching $4.62. About 709,399 shares traded. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 24.44% since April 9, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $419.04 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

The stock increased 12.88% or $3.8 during the last trading session, reaching $33.3. About 8.86M shares traded or 787.32% up from the average. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has declined 33.05% since April 9, 2017 and is downtrending. It has underperformed by 44.60% the S&P500.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.36 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

Investors sentiment increased to 1.4 in 2017 Q4. Its up 0.01, from 1.39 in 2017Q3. It increased, as 29 investors sold Pacira Pharmaceuticals, Inc. shares while 41 reduced holdings. 31 funds opened positions while 67 raised stakes. 40.06 million shares or 3.76% less from 41.63 million shares in 2017Q3 were reported. Baillie Gifford And Co has 370,162 shares for 0.02% of their portfolio. 143,933 were reported by Goldman Sachs Group Inc. Moreover, Jefferies Grp Ltd Liability Company has 0% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Swiss Comml Bank invested in 0% or 69,800 shares. Element Ltd Limited Liability Company stated it has 134,584 shares. Dekabank Deutsche Girozentrale invested in 0.01% or 18,515 shares. Canada Pension Plan Board owns 25,300 shares. Rock Springs Capital Mngmt Ltd Partnership holds 2.29% or 1.11M shares in its portfolio. Us Commercial Bank De has 2,791 shares for 0% of their portfolio. Metropolitan Life New York holds 12,972 shares or 0.01% of its portfolio. Citadel Ltd Company holds 0.01% or 238,567 shares in its portfolio. Comml Bank Of America Corp De reported 183,680 shares. Rhumbline Advisers invested in 0% or 39,592 shares. Raymond James And Associates invested in 68,691 shares or 0.01% of the stock. Great West Life Assurance Can has 3,835 shares for 0% of their portfolio.

Among 22 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pacira Pharmaceuticals has $113 highest and $31 lowest target. $49.32’s average target is 48.11% above currents $33.3 stock price. Pacira Pharmaceuticals had 95 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Outperform” rating by Wedbush on Wednesday, October 19. The company was maintained on Monday, August 7 by Wedbush. The rating was maintained by Mizuho with “Buy” on Wednesday, December 21. Canaccord Genuity downgraded the shares of PCRX in report on Monday, October 30 to “Hold” rating. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Neutral” rating by Goldman Sachs on Thursday, December 1. The stock has “Hold” rating by Cowen & Co on Friday, July 14. As per Wednesday, October 25, the company rating was maintained by Wedbush. The rating was maintained by H.C. Wainwright on Thursday, January 4 with “Buy”. BMO Capital Markets maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) rating on Thursday, August 3. BMO Capital Markets has “Market Perform” rating and $40 target. The firm earned “Buy” rating on Tuesday, January 3 by H.C. Wainwright.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Positions Chart